A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Dec 5, 2022 - P2 | N=60 | Recruiting | Sponsor: Endeavor Biomedicines, Inc. | Trial completion date: Nov 2022 ➔ Aug 2023 | Trial primary completion date: Nov 2022 ➔ Aug 2023
Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|